Enhertu's approval in HER2-ultralow metastatic ... moving it up the treatment pathway as an option after one or more failed endocrine therapies. It was first approved in 2019 for patients with ...

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive metastatic breast cancer, moving the drug up the treatment pathway.

The Food and Drug Administration (FDA) has approved Enhertu ® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection. Kindly note the image has been posted only for representational purposes. Photograph: Kind courtesy Thirdman/Pexels.com With ...

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel therapeutic molecules, such as antibodies and enzymes, to improve molecular ...

First numbering (census) of the Israelites for military purposes and encampment location of each tribe in relation to the Tabernacle About 70 times in the Book of Numbers, we read: The Lord said or ...

In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies how uncertainty of where to find information, coupled with distrust, can damage the relationship between ...

With the rising incidence of cancer in India, AstraZeneca India’s breast cancer medicine trastuzumab deruxtecan (sold under the brand name Enhertu) emerged as the highest-selling new drug brand ...

sudo apt update wget https://repo.radeon.com/amdgpu-install/6.3.1/ubuntu/noble/amdgpu-install_6.3.60301-1_all.deb sudo apt install ./amdgpu-install_6.3.60301-1_all ...